⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
POLYMED - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.4
| Stock Code | POLYMED | Market Cap | 12,985 Cr. | Current Price | 1,281 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 37.4 | Book Value | 285 ₹ | Dividend Yield | 0.27 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,437 ₹ | DMA 200 | 1,793 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.31 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 42.7 | MACD | -46.0 | Volume | 1,71,071 | Avg Vol 1Wk | 1,52,734 |
| Low price | 1,210 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.21 | Debt to equity | 0.08 |
| 52w Index | 4.09 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 33.9 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT declined to ₹83.4 Cr. from ₹89.0 Cr. (-2.04%). ROE (14.2%) and ROCE (18.2%) are moderate, reflecting decent efficiency but not industry-leading.
- Debt & Liquidity: Debt-to-equity at 0.08 indicates very low leverage, ensuring balance sheet stability.
- Valuation: P/E of 37.4 is slightly above industry average (33.9), suggesting mild overvaluation. P/B ~4.5 indicates premium pricing relative to book value. PEG ratio (1.21) reflects reasonable growth-adjusted valuation.
- Technical Indicators: RSI at 42.7 indicates weak momentum; MACD at -46.0 signals bearish trend. Current price ₹1,281 is below DMA 50 (₹1,437) and DMA 200 (₹1,793), showing weakness.
🏢 Business Model & Competitive Advantage
- Poly Medicure (POLYMED) operates in medical devices and consumables, focusing on IV cannulas, dialysis products, and other healthcare equipment.
- Competitive advantage lies in strong R&D, export presence, and diversified product portfolio in critical healthcare segments.
💡 Entry Zone Recommendation
- Entry zone: ₹1,250–₹1,300, near support levels.
- Attractive for long-term investors given healthcare demand, but caution advised due to valuation premium and weak technicals.
📈 Long-Term Holding Guidance
- Moderately suitable for long-term holding due to strong industry tailwinds and low debt.
- Upside potential tied to healthcare infrastructure growth and rising demand for medical devices globally.
✅ Positive
- Low debt-to-equity ratio (0.08).
- Fair PEG ratio (1.21) indicates reasonable growth-adjusted valuation.
- DII holdings increased (+0.31%).
- Strong presence in healthcare exports and medical devices.
⚠️ Limitation
- Moderate ROE (14.2%) and ROCE (18.2%).
- P/E (37.4) slightly above industry average (33.9).
- Dividend yield negligible at 0.27%.
- Stock trading below DMA 50 and DMA 200, showing bearish trend.
📉 Company Negative News
- Quarterly PAT declined from ₹89.0 Cr. to ₹83.4 Cr.
- Bearish technical indicators (MACD negative, RSI weak).
- FII holdings reduced (-0.36%).
📈 Company Positive News
- DII holdings increased (+0.31%).
- Strong export presence in medical devices.
- Low debt ensures financial flexibility.
🏭 Industry
- Medical devices industry P/E at 33.9, slightly lower than Polymed’s valuation.
- Sector growth driven by rising healthcare demand, infrastructure expansion, and global medical device exports.
🔎 Conclusion
- Polymed shows fair valuation and low debt but faces weak profitability and bearish technicals.
- Entry near ₹1,250–₹1,300 is suitable for cautious investors; long-term holding recommended only if earnings stabilize and margins improve.